Press Release – New York, NY – May 18, 2026 – Sichenzia Ross Ference Carmel LLP announced that it represented D. Boral Capital as the exclusive placement agent for the recently priced $2 million registered direct offering of NanoViricides, Inc. (NYSE American: NNVC), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape.
The D. Boral Capital team was led by David Boral, Philip Wiederlight, Mark Iorio, Zach Perotto and Bella Tarbet.
The SRFC team was led by partner Ross Carmel, with associates Jesse Blue and Brady Berman.